Lee, E.-P.; Lin, J.-J.; Chen, S.-H.; Chan, O.-W.; Su, Y.-T.; Hsiao, M.-R.; Hsia, S.-H.; Wu, H.-P.
Clinical Value of Tocilizumab in Reducing Mortality in Refractory Septic Shock in Children with Hematologic and Non-Hematologic Diseases. Cells 2025, 14, 441.
https://doi.org/10.3390/cells14060441
AMA Style
Lee E-P, Lin J-J, Chen S-H, Chan O-W, Su Y-T, Hsiao M-R, Hsia S-H, Wu H-P.
Clinical Value of Tocilizumab in Reducing Mortality in Refractory Septic Shock in Children with Hematologic and Non-Hematologic Diseases. Cells. 2025; 14(6):441.
https://doi.org/10.3390/cells14060441
Chicago/Turabian Style
Lee, En-Pei, Jainn-Jim Lin, Shih-Hsiang Chen, Oi-Wa Chan, Ya-Ting Su, Man-Ru Hsiao, Shao-Hsuan Hsia, and Han-Ping Wu.
2025. "Clinical Value of Tocilizumab in Reducing Mortality in Refractory Septic Shock in Children with Hematologic and Non-Hematologic Diseases" Cells 14, no. 6: 441.
https://doi.org/10.3390/cells14060441
APA Style
Lee, E.-P., Lin, J.-J., Chen, S.-H., Chan, O.-W., Su, Y.-T., Hsiao, M.-R., Hsia, S.-H., & Wu, H.-P.
(2025). Clinical Value of Tocilizumab in Reducing Mortality in Refractory Septic Shock in Children with Hematologic and Non-Hematologic Diseases. Cells, 14(6), 441.
https://doi.org/10.3390/cells14060441
